KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Assets Average (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Assets Average for 18 consecutive years, with $40.4 billion as the latest value for Q1 2026.

  • Quarterly Assets Average rose 3.92% to $40.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $40.4 billion through Mar 2026, up 3.92% year-over-year, with the annual reading at $40.0 billion for FY2025, 3.3% down from the prior year.
  • Assets Average for Q1 2026 was $40.4 billion at Teva Pharmaceutical Industries, roughly flat from $40.3 billion in the prior quarter.
  • The five-year high for Assets Average was $47.4 billion in Q1 2022, with the low at $38.9 billion in Q1 2025.
  • Average Assets Average over 5 years is $42.4 billion, with a median of $42.6 billion recorded in 2023.
  • The sharpest move saw Assets Average decreased 9.87% in 2025, then grew 3.92% in 2026.
  • Teva Pharmaceutical Industries' Assets Average stood at $44.1 billion in 2022, then dropped by 3.05% to $42.8 billion in 2023, then decreased by 5.25% to $40.5 billion in 2024, then decreased by 0.59% to $40.3 billion in 2025, then rose by 0.23% to $40.4 billion in 2026.
  • Per Business Quant, the three most recent readings for TEVA's Assets Average are $40.4 billion (Q1 2026), $40.3 billion (Q4 2025), and $40.0 billion (Q3 2025).